In women with obesity with and without BED, Geliebter et al
As of September 2025, Novo Nordisk has filed 140 lawsuits and issued 1K cease-and-desist letters against GLP-1 compounders
Despite the shared mechanisms of action, these clinical approaches vary considerably in development strategy and trial design
Retatrutide is supplied as a lyophilised powder for in-vitro laboratory research only, not for human or veterinary use
The pill comes in four dose strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg
As a potent acylated peptide, BI 456906 incorporates a C18 fatty acid to prolong its half-life and maintains stability against DPP-4 proteolytic degradation through C-terminal amidation and substitution at the second amino acid [109]